Amita Gupta, MD, MHS

Role: 
Faculty
Professor of Medicine and Public Health; Director, Division of Infectious Diseases
Amita Gupta, MD, MHS

Dr. Gupta is Director of the Division of Infectious Diseases at the Johns Hopkins School of Medicine. She is also Faculty Co-chair of the Johns Hopkins Gupta-Klinsky India Institute, and Professor of Infectious Diseases at the JH School of Medicine. She has a joint appointment in International Health at the JH Bloomberg School of Public Health.

Board certified by the American Board of Internal Medicine in infectious diseases, Dr. Gupta specializes in international public health, clinical research, and education in infectious diseases, HIV/AIDS, tuberculosis (TB), and antimicrobial resistant infections. Since 2003, her work has been focused primarily on India, where she leads several Indo-JHU research collaborations. She serves in leadership positions as Co-Chair of the Faculty Steering Committee of the Johns Hopkins Gupta-Klinsky India Institute, Center Director for the Johns Hopkins Precision Medicine Center for Excellence for COVID-19, the US chair for the Indo-US Vaccine Action Program sponsored RePORT India TB research consortium, which is funded by the US National Institutes of Health (NIH) and the government of India, Department of Biotechnology. She also serves on the global RePORT International Executive Committee, a multilateral global consortia for TB research. She is Co-principal Investigator of the NIH-funded Baltimore-Washington-India HIV and Infectious Diseases Clinical Trials Unit (BWI-CTU), and she is an active clinical investigator in multi-country trials conducted by the AIDS Clinical Trials Group (ACTG) and the International Maternal Pediatric Adolescent AIDS Trials Network (IMPAACT), and has served as protocol chair for high impact studies that have resulted in publications in The New England Journal of Medicine and The Lancet. She is Co-chair of the NIH and AmFAR funded IeDea HIV/TB Working Group and Scientific Committee co-Chair for IMPAACT TB. 

She has been awarded research grants from the NIH, CDC, UNITAID, and several philanthropic foundations to investigate infectious diseases of importance to India and beyond. In 2019, Dr. Gupta was appointed by the US Health and Human Services Secretary for a 4-year term to the NIAID Council, the chief advisory committee for National Institute of Allergy and Infectious Diseases at the U.S. National Institutes of Health. In 2020, she was invited to the Governing Board of the Indo-U.S. Science & Technology Forum

Dr. Gupta is an author of more than 200 peer-reviewed research publications and 7 book chapters on prevention and treatment of HIV, TB, and other infectious diseases, primarily in low- and middle-income settings. She has also mentored more than 35 junior scientists in India and the US to run research studies and submit their own scientific findings to peer-reviewed publications.

Dr. Gupta received an undergraduate degree from MIT, a Doctor of Medicine from Harvard Medical School, and a Master of Health Sciences in clinical investigation from JH Bloomberg School of Public Health. She completed her internal medicine training at San Francisco General Hospital-University of California, San Francisco, followed by a post-doctoral fellowships with the Epidemic Intelligence Service at the US Centers for Disease Control and Prevention (CDC, Foodborne and Diarrheal Diseases) and at the JHU School of Medicine (Infectious Diseases).

Publications on PubMed

Research Program Building and Leadership

  • 2007-present: Chair, IMPAACT P1078, A Randomized Clinical Trial to Evaluate the Safety of Immediate (antepartum-initiated) Versus Deferred Reduction in TB Incidence and Mortality Among HIV-Infected Women and Their Infants in High TB Incidence Settings
  • 2008-present: Protocol Vice-Chair of ACTG 5274, Reducing Early Mortality Among Patients with Advanced HIV Disease: A Randomized Strategy Trial Comparing the Safety and Efficacy of an Individualized Patient TB Treatment Approach to a Public Health Pre-emptive TB Treatment Approach in Resource-Limited Settings (REMEMBER)
  • 2008-2012: Co-investigator ACTG 5267, A Phase I, Safety, Tolerability, and Pharmacokinetic Interaction Study of Single-Dose TMC207 and Efavirenz in Health Volunteers
  •  2008-2012: Co-investigator ACTG 5253 Sensitivity and Specificity of Mycobacterium Tuberculosis Screening and Diagnostics in HIV-Infected Individuals
  • 2009-present: Protocol Vice Chair ACTG 5279, Phase III Clinical Trial of Short-Course Rifapentine/Isoniazid for the Prevention of Active Tuberculosis in HIV-Infected Adults with Latent Tuberculosis Infection
  • 2010: Invited by NIAID, NIH to be a part of a NIH delegation to assess scope of TB research in India. Accompanied the Deputy Director of the Division of AIDS, the Associate Director of International Health Programs, NIAID and other NIH delegates on site visits to 15 Indian institutions throughout the country
  • 2011-2012: Selected to participate in the Johns Hopkins School of Medicine’s Office in Science and Medicine (OWISM) Leadership Program for Women Faculty
  • 2012-present: Member, ACTG TB Transformative Science Group
  • 2014-present: IMPAACT TB Scientific Committee Vice-Chair
  • 2014-present: Co-investigator IMPAACT 2001 Protocol Team, PK and Safety of INH and Rifapentine in Pregnancy
  • 2014-2016: US Co-chair, NIH-India Government, Regional Prospective Observational Research in Tuberculosis (RePORT)
  • 2014-present: Co-chair PHOENIX ACTG A5300/IMPAACT 2003 feasibility study and MDR TB contact prophylaxis trial
  • 2016-present: US Chair, TB Research Consortium, RePORT India
  • 2016-present: Member, Executive Committee, RePORT International
  • 2017: Selected to participate in the Johns Hopkins Leadership Development Program (LDP)
  • 2015-present: Member, Union Interest Group in Maternal-Infant TB working group
  • 2018: Participant, Technical Consultation on Advances in Clinical Trial Design for Development of New TB Treatments, WHO Report generation
  • 2018-present: co Chair, IeDEA TB working group
  • 2019-present: NIAID Council
  • 2020-present: Governing Board Member, Indo-US Science and Technology Forum (IUSTTF)
  • 2020-present: Co-Chair, Faculty Steering Committee, Johns Hopkins Gupta-Klinsky India Institute
  • 2020-present: Center Director, Johns Hopkins Precision Medicine Center for Excellence for COVID-19

 

Pregnancy Associated Immune Responses to Tuberculosis and HIV in India and South Africa (PARTHISA)

Post Date: 
2020-01-14
   |   
Countries: 
   |   
Clinical Sites: 
Dr. Jyoti Mathad is Co-PI of this study. Purpose: Tuberculosis (TB) is a leading cause of maternal mortality, especially among HIV-infected women. Women are most likely to develop active TB during and immediately after pregnancy. The immunologic conditions responsible for this phenomenon are not...

Increasing Market and Public Health Outcomes Through Scaling Up Affordable Access Models of Short Course Preventive Therapy for TB (IMPAACT4TB)

Post Date: 
2019-12-17
   |   
Countries: 
   |   
Clinical Sites: 
Primary Objective: This study is being conducted in Brazil, Cambodia, China, Ethiopia, Ghana, Haiti, India, Indonesia, Kenya, Malawi, Mozambique, South Africa, Tanzania, and Zimbabwe. The overall goal is to reduce TB incidence among (1) people living with HIV who are on antiretroviral therapy, and...

Markers of Lung Impairment in HIV-TB Coinfected Indian Adults

Post Date: 
2019-12-11
   |   
Countries: 
   |   
Clinical Sites: 
Objectives/Aims We will compare the degree of lung impairment between HIV-TB co-infected adults (HIV-TB group) and TB cases without HIV co-infection (TB group) who successfully complete TB therapy. We hypothesize that the HIV-TB group will have a greater degree of lung...

T Cell Biomarkers and T-regulatory Responses to Pediatric TB

Post Date: 
2019-11-21
   |   
Countries: 
   |   
Clinical Sites: 
The goals of this study are to: Validate host T cell biomarkers for diagnosis of pediatric TB Investigate the phenotype and functions of T-regulatory cells in pediatric TB We will use cryopreserved PBMC samples from CTRIUMPH cohorts: Pediatric unconfirmed TB, confirmed TB, latest Tb, and no TB...

Inflammasome Genetics and Tuberculosis Treatment Outcomes

Post Date: 
2019-11-07
   |   
Countries: 
   |   
Clinical Sites: 
Dr. Amita Gupta is a Co-PI on this study. STUDY DESIGN We will conduct a retrospective case-cohort study nested within the CTRIUMPH and EDOTS cohorts to address our study objectives. This will enable us to measure the association of polymorphisms with multiple clinical outcomes simultaneously and...

Evaluation of a Urinary Biomarker Assay for Diagnosis and Test of Cure for Tuberculosis

Post Date: 
2019-09-09
   |   
Countries: 
   |   
Clinical Sites: 
Dr. Jeff Tornheim is PI of this study. METHODS This study will make use of biorepository samples from the Cohort for TB Research by the Indo-US Medical Partnership (CTRIUMPh). CTRIUMPh, funded by the US NIH and Indian Department of Biotechnology, is an academic collaboration between Johns Hopkins...

A5300B/I2003B: Protecting Households On Exposure to Newly Diagnosed Index Multidrug-Resistant Tuberculosis Patients (PHOENIx)

Post Date: 
2019-08-19
   |   
Countries: 
   |   
Clinical Sites: 
Dr. Amita Gupta is Protocol Co-chair for this multinational clinical trial. BACKGROUND The World Health Organization (WHO) estimates that there were 480,000 incident cases of MDR-TB globally in 2015. MDR-TB has been shown to be almost twice as common in TB...

A5300B/I2003B: Protecting Households On Exposure to Newly Diagnosed Index Multidrug-Resistant Tuberculosis Patients (PHOENIx)

Post Date: 
2019-08-19
   |   
Countries: 
   |   
Clinical Sites: 
Dr. Amita Gupta is Protocol Co-chair for this multinational clinical trial. BACKGROUND The World Health Organization (WHO) estimates that there were 480,000 incident cases of MDR-TB globally in 2015. MDR-TB has been shown to be almost twice as common in TB...

Visual Field Loss in HIV-Positive Patients of Non-Infectious HIV Retinopathy

Post Date: 
2019-06-02
   |   
Countries: 
   |   
Clinical Sites: 
New study will assess HIV+ patients and determine the prevalence of visual field loss due to noninfectious HIV retinopathy

Immune Correlates of LTBI in HIV-exposed Infants

Post Date: 
2019-04-29
   |   
Countries: 
About 2 billion people worldwide harbor asymptomatic latent TB infection (LTBI), activation of which results in progression to TB disease. In areas of high tuberculosis (TB) prevalence, infants and young children have a 3-fold higher risk of progression and death from TB at age < 5 years...

Prevalence of Tuberculosis in Severely Malnourished Indian Children

Post Date: 
2018-12-18
   |   
Countries: 
   |   
Clinical Sites: 
This study is funded and conducted under the U.S. National Institutes of Health, Fogarty International Center. PIs are Robert Bollinger, MD, MPH; Dr. Muralidhar Tambe, BJGMC Severely malnourished children are vulnerable population for communicable and non-communicable...

Host RNA Expression for Diagnosis and Monitoring of Pediatric TB in Africa and India

Post Date: 
2018-12-13
   |   
Countries: 
   |   
Clinical Sites: 
We are leveraging the RePORT platform by including a cohort of Indian children together with South African children in a large validation study to study on changes in gene expression profiles during treatment for TB

Characterization of Genomics and Metabolomics among Individuals Highly-Exposed, but Resistant to MTB Infection

Post Date: 
2018-12-13
   |   
Countries: 
   |   
Clinical Sites: 
New study launched in India & South Africa to identify functional relationships between genomics & metabolomics, & to characterize fundamental biological systems underlying resistance to Mtb infection.

Characterization of TB-specific T Cell Responses in Highly-exposed, but Uninfected Health Care Workers in India

Post Date: 
2018-10-25
   |   
Countries: 
   |   
Clinical Sites: 
This study is funded and conducted under the U.S. National Institutes of Health, Fogarty International Center. PIs are Robert Bollinger, MD, MPH; Jyothi Rengarajan, MD, Emory University. Primary Research Question Do health care workers who remain TST...

Vaginal Microbiota in HIV Infected and Uninfected Pregnant Women (Stand Alone)

Post Date: 
2018-10-16
   |   
Countries: 
   |   
Clinical Sites: 
Amita Gupta, MD, MHS, and Shilpa Naik, MD, are PIs for this study; Rupak Shivakoti, PhD, MSPH, is Co-Investigator The makeup of vaginal microbiota is dynamic and may play a role in the birth outcomes of pregnant women. While HIV and pregnancy both uniquely impact vaginal microbiota, the impact of...

Validating a Novel Functional Correlate of Immune Protection of Tuberculosis

Post Date: 
2018-10-03
   |   
Countries: 
   |   
Clinical Sites: 
This C-TRIUMPH study is a longitudinal assessment of PBMC samples of progressors and non-progressors among adult household contacts of active TB patients. The purpose of the study is to probe the functional diversity of T cell responses to several of the antigens encoded by Mtb simultaneously in...

Assessing the Impact of Psychosocial Involvement in Health Care Workers with and without Active Tuberculosis at the Byramjee Jeejeebhoy Government Medical College, Pune, India

Post Date: 
2018-09-13
   |   
Countries: 
   |   
Clinical Sites: 
This study was terminated effective 9/13/2021 This study is funded and conducted under the U.S. National Institutes of Health, Fogarty International Center. The overall goal is to understand the psychosocial involvement in health care workers with and...

Assessment of Depression and Anxiety among HIV-infected Adolescents in Pune, India

Post Date: 
2018-07-22
   |   
Countries: 
   |   
Clinical Sites: 
This study is conducted under the TREAT Asia Network and funded by amfAR. PURPOSE The purpose of this study is to estimate the prevalence of depression and anxiety among adolescents living with HIV in India and their determinants. DESIGN...

Evaluating the Source of Neonatal Bloodstream Infections due to Classically Hospital Acquired Pathogens in the Neonatal Intensive Care Unit in Pune, India

Post Date: 
2018-07-12
   |   
Countries: 
   |   
This study is part of CDC's Safe Healthcare, Epidemiology, and Prevention Research Development (SHEPheRD) Program under Domain 7: International HAI and Other Adverse Healthcare Event Prevention. The PIs for this study are Dr. Julia Johnson of Johns Hopkins and Dr. Shilpa Naik of BJGMC. CoPIs...

Molecular Signatures of Tuberculosis-Diabetes Interaction: Metabolomics Study

Post Date: 
2018-06-15
   |   
Countries: 
   |   
Clinical Sites: 
This study is using stored samples from the Cohort for Tuberculosis Research by the Indo-US Medical Partnership (C-TRIUMPH), under the Regional Prospective Observational Research for Tuberculosis (RePORT) Network, an international TB consortium. Type 2 diabetes mellitus (DM...

Pages

Concomitant pulmonary disease is common among patients with extrapulmonary TB

Post Date: 
2022-08-12
   |   
Countries: 
   |   
Clinical Sites: 
Publication: 
International Journal of Tuberculosis and Lung Disease
Dr. Shivakumar and his group discovered that a high proportion of patients classified as EPTB in India have concomitant PTB. Their results support the need for improved symptom and CXR screening, and recommends routine sputum TB microbiology screening of all Indian patients with EPTB.

Pregnancy in Women with HIV in a Tuberculosis Preventive Therapy Trial

Post Date: 
2022-08-01
   |   
Countries: 
Publication: 
JAIDS
Background: Tuberculosis preventive therapy (TPT) is recommended for people with HIV infection, including during pregnancy. The effect of TPT exposure at conception and during pregnancy is poorly documented. Methods: We report pregnancy outcomes among South African women...

The association of gestational diabetes with HIV infection and tuberculosis in Indian women

Post Date: 
2022-08-01
   |   
Countries: 
Publication: 
The American Journal of Tropical Medicine and Hygiene
Infection of HIV is associated with an increased diabetes risk, which also increases tuberculosis risk. It is unknown if similar associations exist with gestational diabetes (GDM). We screened pregnant women living with and without HIV for GDM using oral glucose tolerance testing. In a subgroup of...

High-Intensity Versus Standard Thromboprophylaxis Among Adults Hospitalized with COVID-19: A Retrospective Cohort Study

Post Date: 
2022-07-22
   |   
Countries: 
Publication: 
Research and Practice in Thrombosis and Haemostasis
Background and Objectives Current clinical guidelines recommend thromboprophylaxis for adults hospitalized with coronavirus disease 2019 (COVID‐19), yet it is unknown whether higher doses of thromboprophylaxis offer benefits beyond standard doses. Methods We studied electronic health records from...

Comparative immune responses to M. tuberculosis in individuals with latent infection or sterile protection against infection

Post Date: 
2022-07-13
   |   
Countries: 
   |   
Clinical Sites: 
Publication: 
bioRxiv
Summary To identify immunologic targets for tuberculosis vaccines more efficacious than BCG, we investigated the immune responses that differentiate individuals with sterile protection against M. tuberculosis (Mtb) infection (TB-resisters) from those who develop latent tuberculosis infection (LTBI-...

Impact of SARS-CoV-2 variants on inpatient clinical outcome

Post Date: 
2022-07-11
   |   
Countries: 
Publication: 
Clinical Infectious Diseases
Background Prior observation has shown differences in COVID-19 hospitalization risk between SARS-CoV-2 variants, but limited information describes hospitalization outcomes. Methods Inpatients with COVID-19 at 5 hospitals in the eastern United States were included if they had hypoxia, tachypnea,...

Isoniazid adherence improves survival and incident tuberculosis at 96 weeks among adults initiating antiretroviral therapy with advanced HIV in multiple high burden settings

Post Date: 
2022-07-03
   |   
Countries: 
Publication: 
Open Forum Infectious Diseases
Background People with human immunodeficiency virus (HIV) and advanced immunosuppression initiating antiretroviral therapy (ART) remain vulnerable to tuberculosis (TB) and early mortality. To improve early survival, isoniazid preventive therapy (IPT) or empiric TB treatment have been evaluated;...

Prevalence of neurotoxicity symptoms among postpartum women on Isoniazid Preventive Therapy and Efavirenz-based treatment for HIV—An exploratory objective of the IMPAACT P1078 randomized trial

Post Date: 
2022-06-21
   |   
Publication: 
BMC Pregnancy and Childbirth
Background This exploratory analysis investigates the prevalence and risk factors of neurocognitive toxicity in postpartum women on HIV treatment in response to a concern of an Isoniazid Preventive Therapy (IPT)/Efavirenz interaction. Trial Design Pregnant women on HIV treatment from countries with...

Diagnostic biomarkers for active tuberculosis: Progress and challenges

Post Date: 
2022-06-20
   |   
Countries: 
Publication: 
EMBO Molecular Medicine
Tuberculosis (TB) is a leading cause of morbidity and mortality from a single infectious agent, despite being preventable and curable. Early and accurate diagnosis of active TB is critical to both enhance patient care, improve patient outcomes, and break Mycobacterium tuberculosis (Mtb)...

Assessing tuberculosis risk in pregnant women from the PRACHITi study using transcriptomics

Post Date: 
2022-06-10
   |   
Countries: 
Publication: 
Clinical Infectious Diseases
A new tuberculosis (TB) diagnostic cartridge assay, which detects a 3-gene TB signature in whole blood, was not diagnostic in women with maternal TB disease in India (area under the curve [AUC] = 0.72). In a cohort of pregnant women, we identified a novel gene set for TB diagnosis (AUC = 0.97) and...

Pharmacokinetics and Safety of 3 Months of Weekly Rifapentine and Isoniazid for Tuberculosis Prevention in Pregnant Women

Post Date: 
2022-06-01
Publication: 
Clinical Infectious Diseases
Background Pregnancy increases the risk of tuberculosis and its complications. A 3-month regimen of weekly isoniazid and rifapentine (3HP) is safe and effective for tuberculosis prevention in adults and children, including those with HIV, but 3HP has not been evaluated in pregnancy. Methods IMPAACT...

A Novel Computer-Based Virtual Counselor-Delivered Alcohol Reduction Intervention : Acceptability, Adaptability and Feasibility among Adults with HIV or TB in Indian Clinical Settings

Post Date: 
2022-05-27
   |   
Countries: 
   |   
Clinical Sites: 
Publication: 
JMIR Formative Research
Background: Unhealthy alcohol use is associated with increased morbidity and mortality among persons with HIV and tuberculosis (TB). Computer-based interventions (CBIs) can reduce unhealthy alcohol use, are scalable, and may improve outcomes among patients with HIV or TB. Objective: We assessed the...

Clinical and Immunological Markers of Pulmonary Impairment among People with HIV(PWH) in India

Post Date: 
2022-05-12
   |   
Countries: 
Publication: 
Open Forum Infectious Diseases
Background Despite anti-retroviral therapy, chronic lung diseases remain an important source of morbidity and mortality in people with HIV (PWH). We sought to identify clinical and immunological markers of pulmonary impairment among PWH in India. Methods 210 adult PWH receiving antiretroviral...

Clinical and Immunological Markers of Pulmonary Impairment among People Living with HIV in India

Post Date: 
2022-05-11
   |   
Countries: 
   |   
Clinical Sites: 
Publication: 
Open Forum Infectious Diseases
Background Despite antiretroviral therapy, chronic lung diseases remain an important source of morbidity and mortality in people with HIV (PWH). We sought to identify clinical and immunological markers of pulmonary impairment among PWH in India. Methods Two hundred ten adult PWH receiving...

High prevalence of TB infection and disease in child household contacts of adults with rifampin-resistant tuberculosis

Post Date: 
2022-05-01
Publication: 
Pediatric Infectious Disease Journal
Background: Household contact (HHC) investigation is an important strategy to identify individuals with tuberculosis (TB) exposure, infection and disease, including those who may benefit from tuberculosis preventive therapy (TPT). Data in children exposed to rifampin-resistant TB are limited...

Cycloserine did not increase depression incidence or severity at standard dosing for MDR-TB

Post Date: 
2022-03-24
   |   
Countries: 
Publication: 
European Respitory Journal
In 2018 cycloserine was elevated to World Health Organization (WHO) group B status for multidrug-resistant tuberculosis (MDR-TB), and is recommended in longer MDR-TB treatment regimens [ 1 ]. Inclusion of cycloserine is associated with improved MDR-TB treatment success and reduced mortality, but is...

Pharmacokinetics and Safety of Three Months of Weekly Rifapentine and Isoniazid for Tuberculosis Prevention in Pregnant Women

Post Date: 
2022-03-05
   |   
Countries: 
Publication: 
Clinical Infectious Diseases
Background Pregnancy increases the risk of tuberculosis and its complications. A 3-month regimen of weekly isoniazid and rifapentine (3HP) is safe and effective for tuberculosis prevention in adults and children, including those with HIV, but 3HP has not been evaluated in pregnancy. Methods IMPAACT...

TB-related Knowledge and Stigma Among Pregnant Women in Low Resource Settings of Pune, India

Post Date: 
2022-02-01
   |   
Countries: 
   |   
Clinical Sites: 
Publication: 
The International Journal of Tuberculosis and Lung Disease,
TB is an important cause of maternal morbidity.1 Studies among adults with TB in several countries have consistently demonstrated that a lack of TB-related knowledge and increased stigma can be a barrier to early diagnosis, seeking treatment and treatment adherence.2–6 India has the highest number...

Implementation of the Comprehensive Unit-based Safety Program to Improve Infection Prevention and Control Practices in Four Neonatal Intensive Care Units in Pune, India

Post Date: 
2022-01-06
   |   
Countries: 
   |   
Clinical Sites: 
Publication: 
Frontiers in Pediatrics
Objective: To implement the Comprehensive Unit-based Safety Program (CUSP) in four neonatal intensive care units (NICUs) in Pune, India, to improve infection prevention and control (IPC) practices. Design: In this quasi-experimental study, we implemented CUSP in four NICUs in Pune, India, to...

Host lipidome and tuberculosis treatment failure

Post Date: 
2022-01-06
   |   
Countries: 
Publication: 
European Respiratory Journal
Introduction: Host lipids play important roles in tuberculosis (TB) pathogenesis. Whether host lipids at TB treatment initiation (baseline) affect subsequent treatment outcomes has not been well characterised. We used unbiased lipidomics to study the prospective association of host lipids with TB...

Pages

Aarti Avinash Kinikar, MD: Pediatrics

BJGMC-JHU Fogarty HIV-TB Program Trainee
Pune, India
Education: MBBS (1984); DCH (1988); MD-Paediatrics (1988), DNB-Paediatrics (2003); MRCP-UK (1995). Medical Education- Grant Medical College – Mumbai University, India.

Sonya Krishnan, MD

Assistant Professor
Baltimore, Maryland
Sonya Krishnan, MD
Sonya Krishnan, MD, is Assistant Professor in the Division of Infectious Diseases at Johns Hopkins University School of Medicine. Her research interests include host biomarkers of HIV/TB and TB outcomes with particular interest in understanding inflammation pathways, their impacts and potential therapies. Dr. Krishnan grew up in Minnesota and completed her undergraduate studies at Carleton College, becoming involved in HIV research while studying abroad in Tanzania. After college she spent two years at the NIH studying predictors of IRIS as well as inflammatory markers in HIV-infected elite...

Amit Kale, MS: Orthopedics

BJGMC-JHU Fogarty HIV-TB Program Trainee
Pune, India
I am working as associate professor in orthopedics. Currently, I am conducting various drug trials for rheumatoid arthritis.

Anita Basavaraj, MD: Gastroenterology

BJGMC-JHU Fogarty HIV-TB Program Trainee
Pune, India
Dr Anita Basavaraj has done her MBBS from Nagpur University with Honors in Surgery (1987). Thereafter she did her MD in Medicine (1990) and her Diplomat of National Board (D.N.B.) in 1992.She has done her post graduate Diploma in geriatric Medicine (P.G.D.G.M.) winning the university Gold Medal by virtue of standing first in the country (2012), which is a distant education venture run by Indira Gandhi National Open University (IGNOU).

Geeta Shrikar Pardeshi, MD: Preventive and Social Medicine

BJGMC-JHU Fogarty HIV-TB Program Trainee
Pune, India
I have led research projects related to Reproductive and Child Health, Sanitation and Infectious diseases. As part of the BJGMC JHU Fogarty training program in HIV-TB, I have research interest in TB epidemiology. I am interested in studying the association of co-morbidities with clinical presentation and treatment outcomes in tuberculosis.

Sunita Girish, PhD: Medical Biochemistry

BJGMC-JHU Fogarty HIV-TB Program Trainee
Pune, India
Education: Ph.D, Pune University, 2005 (Medical Biochemistry) title “Antioxidant Status in Leprosy.” Overview: How to improve health systems to combat various infectious diseases like Leprosy, Tuberculosis and HIV in developing countries, is a research and policy issue that affects many aspects of public health. My research interests include further to understand molecular level changes in cystic fibrosis which is under diagnosed .My interests also involve innovations in molecular techniques dealing with infectious diseases, help governments in developing countries to improve and modify drug...

Pages

Johns Hopkins University Helping India Fight Covid Surge

Post Date: 
2021-05-13
Source: 
CBS Baltimore
Dr. Amita Gupta: “The ramifications of what’s happening now is going to have far-reaching consequences beyond this year.

Hialeah pastor helps sister church half way around the world facing crisis from COVID-19

Post Date: 
2021-05-13
Source: 
Local10.com
Dr. Amita Gupta
“We know with disruptions in supply chain and access to essential services in the setting of a lockdown that food insecurity is a reality and...”

India COVID-19 Outbreak Could 'Spread Around The World,' Expert Warns

Post Date: 
2021-05-13
Source: 
International Business Times
Dr. Amita Gupta
"There was essentially a lot of relaxation of rules," Dr. Amita Gupta, an infectious disease specialist at the Johns Hopkins Bloomberg School of Public Health.

India's COVID-19 Disaster May Be Turning Into an Even Bigger Global Crisis

Post Date: 
2021-05-12
Source: 
Time
Dr. Amita Gupta
Daily confirmed cases in the Himalayan nation increased thirtyfold from April 11 to May 11, when 9,300 infections were recorded.

John Hopkins expert Dr Amita Gupta on India’s covid-19 challenge & future preparedness options

Post Date: 
2021-05-12
Source: 
Financial Express
Dr. Amita Gupta speaks on the lessons one could learn from the different waves of the Covid-19 infection.

Listening from an U.S. expert: Careful evaluation of the power of Indian COVID variant

Post Date: 
2021-05-04
Source: 
Phoenix TV (Hong Kong)
Broadcast in Mandarin; Dr. Amita Gupta's interview is in English

Dr. Amita Gupta on COVID-19 Response in India and US

Post Date: 
2021-05-04
Source: 
Black News Channel
The Black News Channel : Dr. Amita Gupta discusses the COVID response in India and the U.S.

How the US can help the COVID crisis in India

Post Date: 
2021-05-04
Source: 
The Hill
Dr. Amita Gupta
The Hill: Dr. Amita Gupta and colleagues outline 9 steps that the Biden Administration should take to help India respond to COVID-19.

The Dire COVID-19 Crisis in India

Post Date: 
2021-04-29
Source: 
Public Health on Call: Johns Hopkins Podcast Series
Public Health On Call Podcast logo
Public Health on Call: Johns Hopkins Podcast Series. Dr. Amita is interviewed by Dr. Joshua Sharfstein about India's COVID crisis in this podcast series.

India's crushing COVID caseload the result of a 'perfect storm' of factors, experts say

Post Date: 
2021-04-28
Source: 
USA Today
Dr. Amita Gupta
USA Today: Dr. Amita Gupta discusses the dire COVID-19 crisis in India

As COVID Crisis Unfolds in India, Johns Hopkins Rushes to Help

Post Date: 
2021-04-28
Source: 
Johns Hopkins Hub
Filling oxygen tanks in India
JH Hub: The university is working urgently with partners on the ground to offer support and expertise to India, with efforts organized and led by the newly created Johns Hopkins India Institute

A Bold New Chapter Begins for Hopkins and India

Post Date: 
2021-04-26
Source: 
Johns Hopkins Hub
Johns Hopkins India Institute logo
Johns Hopkins Hub: Dr. Amita Gupta leads the launch of the Johns Hopkins India Institute, a university-wide initiative to unite India-related efforts.

ID Spotlight

Post Date: 
2020-11-06
Source: 
Johns Hopkins ID Insider
Johns Hopkins ID Insider: Dr. Gupta: "I chose infectious diseases as a career because I found it to be the most embracing of diversity, and it really nicely combines my interest in medicine, social justice, public health and global affairs."

Trump Briefly Leaves Hospital for Drive-by Photo Op With Supporters

Post Date: 
2020-10-04
Source: 
New York Magazine
Dr. Amita Gupta: “He is not sending the right message [by] going in a car while actively viremic with COVID and receiving therapies.”

Johns Hopkins Researchers Publish COVID-19 ‘Prediction Model’

Post Date: 
2020-09-23
Johns Hopkins News New COVID study findings published in The Annals of Internal Medicine are highlighted

Study Shows Extent, Danger of TB Exposure: Part I

Post Date: 
2020-08-24
Source: 
Medical Daily
Medical Daily: Amita Gupta and Mandar Paradkar are quoted in this report about TB preventive therapy for household contacts of confirmed cases in India

Research Story Tip: International Johns Hopkins Study Says Broad Measures Needed to Prevent TB Spread in India

Post Date: 
2020-08-06
Dr. Mandar Paradkar
Johns Hopkins News Release: News release highlights study findings published in PLOS One by Dr. Mandar Paradkar and colleagues.

Broad measures needed to check spread of TB in India, say researchers

Post Date: 
2020-08-05
Source: 
The Tribune (India)
Drs. Mandar Paradkar and Robert Bollinger are quoted in this article that highlights their recent paper about administration of TB preventive therapy for household contacts of confirmed TB cases in India.

NIH Awards Johns Hopkins Baltimore-Washington-India Trials Group $460,679 in Supplemental COVID-19 Funding

Post Date: 
2020-06-30
The supplement is leveraging existing HIV research infrastructure and personnel for DAIDS-sponsored COVID research

State response panel, experts meet to strengthen testing

Post Date: 
2020-04-24
Source: 
Hindustan Times
The Health Sector Response and Procurement Committee (HSRPC) of Punjab held a meeting over videoconference with experts from Johns Hopkins University, USA; Centre for Policy Research, New Delhi and PGIMER, Chandigarh, to discuss approaches to strengthen testing strategy in the state. “The state...

Pages